Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial

The Alzheimer's Association announced the launch of the PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy) at the 2026 Alzheimer's Association International Conference (AAIC) in London. The global trial will evaluate whether combining a multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 receptor agonist, further reduces cognitive decline risk beyond what lifestyle intervention alone has shown.¹

"PROTECT-Cog builds directly on what we learned from U.S. POINTER and takes the next critical step in prevention science," Maria C. Carrillo, PhD, chief science officer and medical affairs lead at the Alzheimer's Association and principal investigator of the study, said in a statement.¹ "By testing a combined approach that targets both lifestyle and biology, we have the opportunity to better understand how to meaningfully reduce the risk of cognitive decline before symptoms begin."

The study extends the Association's existing prevention infrastructure, built through U.S. POINTER, LatAm FINGERS, and the World-Wide FINGERS Network. "The Alzheimer's Association is uniquely positioned to lead this next generation of dementia prevention research," Heather M. Snyder, PhD, senior vice president of medical and scientific relations at the Association and staff lead on the project, said in a statement.¹

What U.S. POINTER showed

PROTECT-Cog follows directly from U.S. POINTER (NCT03688126), a 2-year, 5-site randomized trial that enrolled 2,111 cognitively unimpaired older adults (mean age, 68.2 years) at elevated risk for cognitive decline based on sedentary lifestyle, suboptimal diet, and additional cardiometabolic or demographic risk factors. Participants were randomized to a structured intervention, featuring 38 facilitated team meetings, supervised aerobic and resistance exercise, MIND diet coaching, and web-based cognitive training, or a lower-intensity self-guided intervention using public education materials and periodic peer meetings.²

The structured group showed significantly greater improvement in global cognitive function, with composite z-scores increasing by 0.243 SD per year versus 0.213 SD per year in the self-guided group, a between-group difference of 0.029 SD annually (95% CI, 0.008-0.050; P = .008).² The benefit held across APOE ε4 carriers and noncarriers alike. According to the Alzheimer's Association, the structured intervention's cognitive benefit was equivalent to roughly one to two years of cognitive advantage, alongside secondary improvements in frailty, sleep apnea, and blood pressure regulation.¹

Study design

PROTECT-Cog will enroll older adults at increased risk for cognitive decline and randomize them to one of two lifestyle approaches: a structured program with intensive coaching, or a structured-lite program using the same core content with fewer touchpoints. A subset will also receive a drug intended to support healthier metabolism and immune function, allowing investigators to identify which combination most effectively delays MCI while tracking effects on frailty, quality of life, and overall health.¹ Participants will be followed for three years, with evaluations every six months.

GLP-1 drugs and dementia risk: a mixed picture

The rationale for adding a metabolic drug arm rests on a divided evidence base. Large real-world healthcare datasets have associated GLP-1 receptor agonist use with a 40% to 70% lower relative risk of dementia compared with other diabetes medications, with the strongest protective association in patients with obesity or elevated BMI.¹ Mechanistic studies point to effects on brain inflammation, metabolism, and vascular health as plausible explanations.¹

That observational signal has not held up in dedicated randomized testing. In the phase 3 EVOKE and EVOKE+ trials, oral semaglutide (14 mg daily) was evaluated in 3,808 participants with biomarker-confirmed early-stage Alzheimer disease. Semaglutide improved AD-related biomarkers, including a roughly 30% reduction in C-reactive protein, but did not slow clinical decline on the CDR-SB scale relative to placebo, and the planned 1-year extension was discontinued following the negative topline readout.^3,4

"Novo has noted an improvement of Alzheimer's-related biomarkers in both trials," Howard Fillit, MD, co-founder and chief science officer of the Alzheimer's Drug Discovery Foundation, said in a statement.¹ "We look forward to seeing further results at CTAD, as this may suggest a path forward for semaglutide as part of a combination therapy approach."³ It is this combination framing, rather than GLP-1 monotherapy, that PROTECT-Cog is designed to test.

Click here for more AAIC 2026 coverage.

REFERENCES
1. Alzheimer's Association launches "PROTECT-Cog" study to test U.S. POINTER lifestyle and GLP-1 or similar drug to cut risk of cognitive decline. News release. Alzheimer's Association. July 13, 2026. Accessed July 16, 2026. https://www.prnewswire.com/news-releases/alzheimers-association-launches-protect-cog-study-to-test-us-pointer-lifestyle-and-glp-1-or-similar-drug-to-cut-risk-of-cognitive-decline-302823408.html
2. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. doi:10.1001/jama.2025.12923. https://jamanetwork.com/journals/jama/fullarticle/2837046
3. Readout of phase 3 semaglutide trials marks critical moment in Alzheimer's research and suggests potential for combination therapies. News release. Alzheimer's Drug Discovery Foundation. November 24, 2025. Accessed July 16, 2026. https://www.prnewswire.com/news-releases/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies-302624675.html
4. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00459-9/fulltext